CL2012003291A1 - Metodo para reducir la cantidad de una serina proteasa o de un zimógeno de serina proteasa en una composicion de proteinas derivadas de plasma de interés; metodo para preparar una composicion del factor h con una cantidad reducida de una serina proteasa o de un zimógeno de serina proteasa; metodo para preparar composicion de un inhibidor de inter-alfa-tripsina. - Google Patents

Metodo para reducir la cantidad de una serina proteasa o de un zimógeno de serina proteasa en una composicion de proteinas derivadas de plasma de interés; metodo para preparar una composicion del factor h con una cantidad reducida de una serina proteasa o de un zimógeno de serina proteasa; metodo para preparar composicion de un inhibidor de inter-alfa-tripsina.

Info

Publication number
CL2012003291A1
CL2012003291A1 CL2012003291A CL2012003291A CL2012003291A1 CL 2012003291 A1 CL2012003291 A1 CL 2012003291A1 CL 2012003291 A CL2012003291 A CL 2012003291A CL 2012003291 A CL2012003291 A CL 2012003291A CL 2012003291 A1 CL2012003291 A1 CL 2012003291A1
Authority
CL
Chile
Prior art keywords
serine protease
composition
zymogen
preparing
amount
Prior art date
Application number
CL2012003291A
Other languages
English (en)
Spanish (es)
Inventor
Sonja Svatos
Wolfgang Teschner
Hans-Peter Schwarz
Ruth Madlener
Alfred Weber
Azra Pljevljakovic
Original Assignee
Baxter Healthcare Sa
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42727304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012003291(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US12/842,944 external-priority patent/US8304524B2/en
Application filed by Baxter Healthcare Sa, Baxter Int filed Critical Baxter Healthcare Sa
Publication of CL2012003291A1 publication Critical patent/CL2012003291A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A61K39/39525—Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/12—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the preparation of the feed
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424—Elution mode
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/02—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material
    • B01J20/10—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising silica or silicate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
CL2012003291A 2010-05-26 2012-11-23 Metodo para reducir la cantidad de una serina proteasa o de un zimógeno de serina proteasa en una composicion de proteinas derivadas de plasma de interés; metodo para preparar una composicion del factor h con una cantidad reducida de una serina proteasa o de un zimógeno de serina proteasa; metodo para preparar composicion de un inhibidor de inter-alfa-tripsina. CL2012003291A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2010202125A AU2010202125B1 (en) 2010-05-26 2010-05-26 A method to produce an immunoglobulin preparation with improved yield
US12/789,365 US8993734B2 (en) 2010-05-26 2010-05-27 Method to produce an immunoglobulin preparation with improved yield
US12/842,944 US8304524B2 (en) 2009-07-23 2010-07-23 Manufacture of factor H (FH) and FH-derivatives from plasma

Publications (1)

Publication Number Publication Date
CL2012003291A1 true CL2012003291A1 (es) 2013-10-04

Family

ID=42727304

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2012003291A CL2012003291A1 (es) 2010-05-26 2012-11-23 Metodo para reducir la cantidad de una serina proteasa o de un zimógeno de serina proteasa en una composicion de proteinas derivadas de plasma de interés; metodo para preparar una composicion del factor h con una cantidad reducida de una serina proteasa o de un zimógeno de serina proteasa; metodo para preparar composicion de un inhibidor de inter-alfa-tripsina.
CL2012003290A CL2012003290A1 (es) 2010-05-26 2012-11-23 Metodo para preparar una composicion enriquecida en igg a partir de plasma; composicion acuosa de igg; composicion farmaceutica que comprende dicha composicion acuosa; uso de dicha composicion para tratar enfermedad autoinmune o infeccion aguda
CL2014003430A CL2014003430A1 (es) 2010-05-26 2014-12-17 Método para producir una preparacion de inmunoglobulina con un rendimiento mejorado

Family Applications After (2)

Application Number Title Priority Date Filing Date
CL2012003290A CL2012003290A1 (es) 2010-05-26 2012-11-23 Metodo para preparar una composicion enriquecida en igg a partir de plasma; composicion acuosa de igg; composicion farmaceutica que comprende dicha composicion acuosa; uso de dicha composicion para tratar enfermedad autoinmune o infeccion aguda
CL2014003430A CL2014003430A1 (es) 2010-05-26 2014-12-17 Método para producir una preparacion de inmunoglobulina con un rendimiento mejorado

Country Status (26)

Country Link
US (6) US8993734B2 (enExample)
EP (6) EP2803349B1 (enExample)
JP (6) JP5876474B2 (enExample)
KR (3) KR101593265B1 (enExample)
CN (5) CN102970975B (enExample)
AR (4) AR076800A1 (enExample)
AU (8) AU2010202125B1 (enExample)
BR (2) BR112012029893B1 (enExample)
CA (2) CA2800155A1 (enExample)
CL (3) CL2012003291A1 (enExample)
CO (2) CO6660438A2 (enExample)
DK (4) DK2554160T3 (enExample)
EA (4) EA023446B1 (enExample)
ES (4) ES2536093T3 (enExample)
FI (1) FI4039249T3 (enExample)
HK (1) HK1213790A1 (enExample)
HR (4) HRP20141109T1 (enExample)
HU (1) HUE064400T2 (enExample)
IL (2) IL223150A0 (enExample)
MX (4) MX349815B (enExample)
MY (3) MY173299A (enExample)
PL (5) PL2554160T3 (enExample)
PT (4) PT2554160E (enExample)
SG (3) SG185724A1 (enExample)
TW (3) TWI531577B (enExample)
WO (1) WO2011149472A1 (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI489994B (zh) 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
US8546548B2 (en) 2009-05-27 2013-10-01 Baxter International Inc. Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
PT2477603E (pt) * 2009-09-17 2016-06-16 Baxalta Inc Co-formulação estável de hialuronidase e imunoglobulina e métodos para a sua utilização
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
US8772462B2 (en) 2010-05-26 2014-07-08 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
EP2596014B1 (en) * 2010-07-23 2018-11-28 Baxalta GmbH Manufacture of inter-alpha-inhibitor proteins (iaip) from plasma
EP2719704B1 (en) * 2011-04-08 2016-07-20 Universidad De Costa Rica Method for producing injectable formulations of blood-derived protein materials, and materials obtained using said method
WO2013090636A1 (en) 2011-12-13 2013-06-20 Baxter International Inc. Measurement of autoantibodies at low conductivity conditions with increased sensitivity
TWI629283B (zh) * 2012-02-23 2018-07-11 巴克斯歐塔公司 來自血漿中的免疫球蛋白之ｉ-ｉｖ-１部分沉澱
RU2487725C1 (ru) * 2012-03-15 2013-07-20 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации (ФГУП "НПО "Микроген" Минздрава России) Способ получения концентрированного иммуноглобулинового препарата для подкожного введения
AU2013203043B2 (en) 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
CN103197053B (zh) * 2013-03-15 2015-02-18 上海市血液中心 一种抗IgA抗体检测试剂盒
CN104086642A (zh) * 2014-07-03 2014-10-08 成都蓉生药业有限责任公司 血液制品中fi+iii上清的制备方法
CN104086646B (zh) * 2014-07-03 2018-10-09 成都蓉生药业有限责任公司 血液制品中fv沉淀的制备方法
CN104072601A (zh) * 2014-07-03 2014-10-01 成都蓉生药业有限责任公司 血液制品中fii沉淀的制备方法
GB201413227D0 (en) * 2014-07-25 2014-09-10 Bioproducts Lab Ltd Process
WO2016064955A1 (en) 2014-10-21 2016-04-28 The General Hospital Corporation Methods of diagnosis and treatment of tuberculosis and infection
CN204424090U (zh) 2014-11-28 2015-06-24 比亚迪股份有限公司 薄膜电容器
WO2016161423A1 (en) * 2015-04-02 2016-10-06 Kieu Hoang Process of cloning and further purification to make a recombinant intravenous immunoglobulin
CN107921079A (zh) * 2015-04-02 2018-04-17 K·黄 由组分iii制造静脉注射免疫球蛋白的方法
US10583179B2 (en) * 2015-04-02 2020-03-10 Kieu Hoang Method of manufacturing and purifying prothrombin complex concentrate from Fraction III for intravenous injection and a method of curing and preventing Hemophilia A with inhibitors or Hemophilia B in patients infected with HIV-1 and HIV-2
US20170233458A1 (en) * 2015-09-29 2017-08-17 Kieu Hoang Method of manufacturing intravenous immunoglobulin from fraction iii
WO2017062536A2 (en) * 2015-10-06 2017-04-13 Kieu Hoang A method of manfacturing prothrombin complex concentrate from fraction iii and non-prothrombin complex concentrate from fraction iv
CN106800583A (zh) * 2015-11-26 2017-06-06 上海洲跃生物科技有限公司 一种速溶无析出的冻干人纤维蛋白原制备工艺
WO2017176735A1 (en) 2016-04-05 2017-10-12 Haemonetics Corporation Methods and devices for the enrichment of immunoglobulin from blood
EP3275897A1 (en) * 2016-07-27 2018-01-31 Biotest AG Process for preparing immunoglobulin compositions
US11510871B2 (en) 2016-09-16 2022-11-29 Leukocare Ag Method for producing low viscous and highly concentrated biopharmaceutical drug products in liquid formulation
EP3512939B1 (en) 2016-09-16 2026-06-17 Leukocare AG A novel method for obtaining efficient viral vector-based compositions for vaccination or gene therapy
US20190216925A1 (en) * 2016-09-16 2019-07-18 Leukocare Ag A Novel Method for Stabilization of a Biopharmaceutical Drug Product During Processing
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
EP3612221A1 (en) * 2017-04-21 2020-02-26 CSL Behring AG Immunoglobulin products for use in the treatment of chronic inflammatory demyelinating polyneuropathy
WO2019086463A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
EP3728287B1 (en) * 2017-12-19 2024-04-10 CSL Behring Lengnau AG Protein purification and virus inactivation with alkyl glycosides
EP3774894A1 (en) 2018-04-12 2021-02-17 Amgen Inc. Methods for making stable protein compositions
CN108733099B (zh) * 2018-05-31 2020-08-11 上海药明生物技术有限公司 低pH孵育和中和的自动调节系统及方法
US20220389479A1 (en) * 2019-10-11 2022-12-08 Takeda Pharmaceutical Company Limited HEPARIN-INSENSITIVE ASSAY FOR FACTOR XIa
WO2021091855A1 (en) 2019-11-04 2021-05-14 Alkahest, Inc. Blood plasma fractions for use in muscle regeneration
CA3157446A1 (en) 2019-11-20 2021-05-27 Csl Behring Ag Method for extracting a protein from a precipitate and method for precipitating impurities
MX2022011950A (es) * 2020-03-31 2022-10-21 Takeda Pharmaceuticals Co Metodo para producir una preparacion de inmunoglobulina a partir de plasma con reduccion del inhibidor de c-1.
EP4118108A4 (en) 2020-04-10 2024-05-15 Plasma Technologies, LLC COMPOSITIONS AND METHODS FOR HIGHLY EFFICIENT SIMPLIFIED PROTEIN ISOLATION
CN111961130B (zh) * 2020-08-31 2021-09-10 华兰生物工程重庆有限公司 一种从血浆中提取并分离IgM和IgG的方法
CA3189976A1 (en) * 2020-10-01 2022-04-07 Takeda Pharmaceutical Company Limited Plasma fractionation process utilizing spray-dried human plasma
CN114456271A (zh) * 2020-11-10 2022-05-10 新疆德源生物工程有限公司 一种Rho(D)人免球蛋白的生产工艺
JP2024501025A (ja) 2020-12-28 2024-01-10 プラズマ テクノロジーズ エルエルシー 免疫グロブリンｇのプロセススケールでの単離のためのシステム及び方法
CN112574296B (zh) * 2020-12-30 2023-05-19 中国医学科学院输血研究所 一种模拟IVIg的多人份混合人血浆IgG样品的分离纯化方法
MX2024001187A (es) 2021-07-29 2024-02-27 Csl Behring Ag Metodo para purificar inmunoglobulina g y usos de la misma.
CA3236213A1 (en) 2021-10-27 2023-05-04 Eugene ZURLO Compositions and methods for isolating proteins
KR102779378B1 (ko) * 2022-01-05 2025-03-12 한양대학교 에리카산학협력단 1-알릴이소크로만 유도체와 이의 제조방법
KR20230121373A (ko) * 2022-02-11 2023-08-18 주식회사 녹십자 인자 xiii의 정제방법
US20250188120A1 (en) 2022-03-07 2025-06-12 Takeda Pharmaceutical Company Limited Affinity chromatographic production of clinical human igg products
EP4490042A4 (en) 2022-03-08 2026-03-04 Equashield Medical Ltd FLUID TRANSFER STATION IN A ROBOTIC PHARMACEUTICAL PREPARATION SYSTEM
CN119300842A (zh) 2022-05-02 2025-01-10 武田药品工业株式会社 通过超滤从血浆制备科恩池浓缩物的方法
KR20250025642A (ko) 2022-06-22 2025-02-24 아제로닉스 에스에이 만성 염증성 탈수초성 다발신경병증과 같은 신경계의 질환 또는 장애의 치료에 사용하기 위한 알파1-항트립신
KR20250161658A (ko) 2023-03-29 2025-11-17 체에스엘 베링 아게 부작용과 관련된 면역글로불린을 식별하는 방법
AU2024290612A1 (en) 2023-07-04 2026-02-05 Csl Behring Ag Method of purification
AU2024351533A1 (en) 2023-09-26 2026-03-19 Takeda Pharmaceutical Company Limited IMMUNOGLOBULIN FORMULATIONS DEPLETED IN IgA
WO2025085544A1 (en) * 2023-10-17 2025-04-24 Plasma Technologies, Llc Integrated process for isolation of plasma proteins
PL249601B1 (pl) * 2024-04-30 2026-05-18 Deveris Polska Spolka Z Ograniczona Odpowiedzialnoscia Sposób wzbogacania preparatów plazmy krwi drobiowej w immunoglobulinę G (IgG)
WO2025229607A1 (en) 2024-05-03 2025-11-06 Csl Behring Ag Systems and methods for solid-liquid separation
WO2026074476A1 (en) 2024-10-02 2026-04-09 Csl Behring Ag Method of detecting autoantibodies against fc epsilon receptor i
WO2026078636A1 (en) 2024-10-11 2026-04-16 Csl Behring Ag Methods of monitoring chromatographic purification of proteins
WO2026093923A1 (en) 2024-10-29 2026-05-07 Csl Behring Ag Method for detection of a plasma protein

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2390074A (en) * 1942-02-09 1945-12-04 Research Corp Protein product and process
SE348942B (enExample) 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
US4056614A (en) 1972-09-22 1977-11-01 Marc Bonneau Immunity depressant medicine
US3998946A (en) * 1975-04-23 1976-12-21 The Regents Of The University Of Minnesota Fibrinogen-free plasminogen-plasmin-free plasma and method of preparing and using same
DE2801123C2 (de) * 1977-01-26 1986-01-02 Armour Pharma GmbH & Co KG, 3440 Eschwege Verfahren zur Herstellung eines intravenös applizierbaren Serumeiweiß-Präparates
US4136094A (en) 1977-08-31 1979-01-23 The Regents Of The University Of Minnesota Preparation of intravenous human and animal gamma globulins and isolation of albumin
US4296027A (en) 1977-08-31 1981-10-20 The Regents Of The University Of Minnesota Pure intravenous human and animal gamma globulins
US4550019A (en) * 1978-03-22 1985-10-29 South Africa Inventions Development Corporation Manufacture and use of fowl egg antibodies
US4357272A (en) * 1978-03-22 1982-11-02 The South African Inventions Development Corporation Recovering purified antibodies from egg yolk
DE2901822A1 (de) * 1979-01-18 1980-07-31 Biotest Serum Institut Gmbh Verfahren zur herstellung einer fuer die intravenoese applikation geeigneten immunglobulinloesung, die igm in ankonzentrierter form enthaelt
DE2902158A1 (de) 1979-01-20 1980-07-31 Biotest Serum Institut Gmbh Verfahren zur herstellung von fibrinogen, einem die gerinnungsfaktoren ii, vii, ix und x enthaltenden prothrombinkomplex, antithrombin iii und einer loesung von lagerstabilen serumproteinen
US4228154A (en) 1979-02-26 1980-10-14 Armour Pharmaceutical Company Purification of plasma albumin by ion exchange chromatography
US4378346A (en) * 1979-08-15 1983-03-29 Tankersley Donald L Intravenously injectable solution of plasma protein fraction free from bradykinin, kininogen and prekallikrein activators and processes for its production
US4499073A (en) * 1981-08-24 1985-02-12 Cutter Laboratories, Inc. Intravenously injectable immune serum globulin
JPS5855432A (ja) 1981-09-29 1983-04-01 Fujirebio Inc 静脈注射用免疫グロブリンの製法
US4439358A (en) 1982-06-17 1984-03-27 Miles Laboratories, Inc. Method of preparing alpha-1-proteinase inhibitor
US4624780A (en) 1982-06-28 1986-11-25 Alpha Therapeutic Corporation Fractionation of blood plasma
DE3247150A1 (de) 1982-12-21 1984-06-28 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Gerinnungsaktive plasmaproteinloesung, verfahren zu ihrer herstellung und ihre verwendung zur behandlung von stoerungen des haemostasesystems
DK166763B1 (da) 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
US5061237A (en) 1985-07-02 1991-10-29 Cytomed Medizintechnik Gmbh Method of purifying whole blood
DE3523615A1 (de) 1985-07-02 1987-01-15 Cytomed Medizintechnik Medizinisches geraet, insbesondere kanuele, katheter oder implantat
JPH0742235B2 (ja) 1985-11-08 1995-05-10 三共株式会社 自己免疫性疾病の予防・治療剤
US5136094A (en) 1988-03-10 1992-08-04 Air Products And Chemicals, Inc. Process for the synthesis of secondary formamides
US5055447A (en) 1988-07-28 1991-10-08 Genentech, Inc. Method and compositions for the treatment and prevention of septic shock
US4897465A (en) 1988-10-12 1990-01-30 Abbott Laboratories Enrichment and concentration of proteins by ultrafiltration
JP2871709B2 (ja) 1988-11-21 1999-03-17 住友製薬株式会社 免疫グロブリンｇ結合活性を有する新規な蛋白質プロテインｈ、該蛋白質をコードする遺伝子及び該蛋白質の製造法
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
EP0440509A3 (en) * 1990-02-02 1991-12-18 Common Services Agency Novel cell growth medium components and process for producing same
EP0447585B2 (de) * 1990-03-22 2003-05-07 Biotest Pharma Gmbh Verfahren zur Herstellung eines intravenös verträglichen Immunglobulin-G-Präparates
US5130451A (en) * 1991-03-28 1992-07-14 Amoco Corporation Process for preparing carboxyaryl phosphates
US5324425A (en) * 1992-08-26 1994-06-28 Ellison Billy L Method and apparatus for removing solids from aqueous wash solutions
FR2706466B1 (fr) 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
FR2711371B1 (fr) 1993-10-18 1995-12-29 Aetsrn Procédé de préparation d'un concentré d'inter-alpha-trypsine inhibiteur à usage thérapeutique et concentré obtenu.
US5610285A (en) 1994-08-24 1997-03-11 Bayer Corporation Purification of α-1 proteinase inhibitor using novel chromatographic separation conditions
GB9418092D0 (en) 1994-09-08 1994-10-26 Red Cross Found Cent Lab Blood Organic compounds
DE4435485C1 (de) 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
AUPN858596A0 (en) 1996-03-08 1996-04-04 Csl Limited Filtration of plasma precipitates using cellulose filter aid
TW491855B (en) * 1996-08-07 2002-06-21 Csl Ltd Purification of immunoglobulins
US5783640A (en) * 1997-03-04 1998-07-21 The Goodyear Tire & Rubber Company Rubber compositions containing a disodium salt of 2, 2'-dithiosalicyclic acid
CA2232420A1 (en) 1997-03-19 1998-09-19 The Green Cross Corporation Immunoglobulin preparation and preparation process thereof
GB9705810D0 (en) 1997-03-20 1997-05-07 Common Services Agency Intravenous immune globulin
AT407114B (de) 1997-06-10 2000-12-27 Immuno Ag Alpha 1-antitrypsin-präparation sowie verfahren zu deren herstellung
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
CA2251342A1 (en) 1997-10-23 1999-04-23 Yutaka Hirao Room temperature storable immunoglobulin preparation for intravenous injection
US20020114802A1 (en) 1998-02-10 2002-08-22 Tjellstrom Bo Arthur Einar Oral immunoglobulin treatment for inflammatory bowel disease
AT406873B (de) 1998-02-25 2000-10-25 Immuno Ag Verfahren zur abreicherung von pathogenen aus proteinhaltigen lösungen
DK2270044T3 (en) 1998-06-09 2015-01-26 Csl Behring Ag Liquid immunoglobulin G (IgG) product
ID27417A (id) 1998-06-09 2001-04-05 Statens Seruminstitut Proses untuk memproduksi immunoglobulin untuk pemberian melalui intravena dan produk-produk immunoglobulin lainnya
AUPQ026799A0 (en) 1999-05-10 1999-06-03 Csl Limited Method of increasing protein stability by removing immunoglobulin aggregates
DE19932782A1 (de) * 1999-07-14 2001-01-18 Biotest Pharma Gmbh Verfahren zur chromatographischen Fraktionierung von Plasma oder Serum, so erhaltene Präparate und deren Verwendung
AU775149B2 (en) 1999-10-21 2004-07-22 Alcon Inc. Sub-tenon drug delivery
DE10008519C1 (de) 2000-02-21 2001-07-12 Dica Technologies Ag Verfahren und Kommunikationseinrichtungen zum Aufbau von gesicherten E-Mail-Verkehr zwischen Mail-Domains des Internet
DE10008619A1 (de) * 2000-02-24 2001-09-06 Immuno Vet As Lynge Mikroorganismenfreies IgG-Präparat, Verfahren zu seiner Herstellung und seine Verwendung in der Tieraufzucht und in der Tiermast
SE0001128D0 (sv) 2000-03-30 2000-03-30 Amersham Pharm Biotech Ab A method of producing IgG
US20020098182A1 (en) 2000-09-28 2002-07-25 Richard Weisbart Treatment of immune-mediated diseases by oral administration of plasma fractions enriched in immunoglobulin G
AU2002216968A1 (en) 2000-10-13 2002-04-22 Octapharma Ag Plasma fraction containing bikunin, method for the production thereof and use of the same
FR2824568B1 (fr) 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
WO2003028668A2 (en) 2001-10-04 2003-04-10 Protein Therapeutics, Inc. Gammaglobulin treatment of immune disorders
US6893639B2 (en) 2001-10-19 2005-05-17 Hemacare Corporation Method for high yield purification of immune globulins from blood plasma and blood plasma intermediates
US7777006B2 (en) 2002-12-31 2010-08-17 Csl Behring L.L.C. Method for purification of alpha-1-antitrypsin
KR20060015574A (ko) * 2003-05-23 2006-02-17 노보 노르디스크 헬스 케어 악티엔게젤샤프트 용액 중 단백질 안정화
WO2005012354A1 (en) 2003-07-31 2005-02-10 Zlb Behring Gmbh Method for extending the half-life of fviii
EP1664119A1 (en) 2003-09-08 2006-06-07 Medical Research Council Method for the treatment or prophylaxis of tuberculosis
US20050054003A1 (en) 2003-09-10 2005-03-10 Stenland Christopher J. Prion clearance using particulate metal oxides
US7932365B2 (en) 2003-11-08 2011-04-26 Pro Thera Biologics, Llc Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
US20070244305A1 (en) 2004-01-30 2007-10-18 Suomen Punainen Risti Veripalvelu Process for The Manufacture of Virus Safe Immunoglobulin
CA2557229C (en) 2004-02-27 2012-07-10 Octapharma Ag A method of providing a purified, virus safe antibody preparation
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
US7745389B2 (en) 2005-02-14 2010-06-29 University Of Iowa Research Foundation Methods for treatment of age-related macular degeneration
WO2009005877A2 (en) * 2007-04-20 2009-01-08 Regents Of The University Of Colorado Alpha-i antitrypsin having no significant serine protease inhibitor activity
US8715649B2 (en) 2005-06-07 2014-05-06 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods of use for alpha-1 antitrypsin having no significant serine protease inhibitor activity
US7807435B2 (en) 2005-08-11 2010-10-05 Baxter International Inc. Method for the purification of alpha-1 proteinase inhibitor (a1PI)
JP2009508822A (ja) 2005-09-19 2009-03-05 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 慢性腎症の処置のためのｈ因子およびその製造
FR2894145B1 (fr) 2005-12-07 2008-10-17 Lab Francais Du Fractionnement Utilisation de facteur h du complement a titre de medicament
EP1987054A1 (en) 2006-01-25 2008-11-05 Octapharma AG Purification and use of a factor for supporting wound healing
US8476234B2 (en) 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
EP1852443A1 (en) * 2006-05-05 2007-11-07 Leukocare AG Biocompatible three dimensional matrix for the immobilization of biological substances
DE102007001521A1 (de) * 2007-01-10 2008-07-17 Matthias, Torsten, Dr. Verwendung von Cohn-Oncley-Fraktionen II und II/III zur Behandlung des systemischen Lupus erythematodes
ES2595059T3 (es) * 2007-03-20 2016-12-27 Csl Behring Gmbh Métodos para la producción a escala industrial de preparados terapéuticos del Factor H del complemento a partir de plasma humano
DE202007004346U1 (de) 2007-03-21 2007-10-31 Rehau Ag + Co Rohranordnung
PL2167117T3 (pl) 2007-06-13 2013-01-31 Csl Behring Gmbh Zastosowanie stabilizowanego VWP preparatu FVIII do podawania pozanaczyniowego w terapii i profilaktyce zaburzeń krzepliwości krwi
AU2008286361B2 (en) 2007-08-13 2013-09-26 Takeda Pharmaceutical Company Limited IVIG modulation of chemokines for treatment of multiple sclerosis, Alzheimer's disease, and Parkinson's disease
JP5400050B2 (ja) * 2007-10-02 2014-01-29 シーエスエル、リミテッド 治療用抗体の精製法および使用法
EP2244814B1 (en) 2007-12-28 2021-06-02 Takeda Pharmaceutical Company Limited Recombinant vwf formulations
CN101279246B (zh) 2007-12-28 2011-07-27 华侨大学 一种嗜硫性磁性复合微球的制备方法和用此复合微球分离免疫球蛋白g的方法
CN101249265B (zh) * 2008-04-11 2010-10-27 三九集团湛江开发区双林药业有限公司 静脉注射用人乙肝免疫球蛋白及其制备方法
PT2271382E (pt) 2008-04-15 2013-05-07 Grifols Therapeutics Inc Ultrafiltração em dois andares/diafiltração
JP5793076B2 (ja) 2008-05-28 2015-10-14 プロセラ バイオロジクス， インコーポレイテッド 血液由来インター−アルファ−阻害タンパク質の調製及び組成物。
EP2865760B1 (en) 2008-06-24 2017-10-11 CSL Behring GmbH Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life
CN201169579Y (zh) * 2008-06-30 2008-12-24 山东泰邦生物制品有限公司 一种人血白蛋白分离用乙醇雾化扩散装置
EP2349314B1 (en) 2008-10-21 2013-02-27 Baxter International Inc. Lyophilized recombinant vwf formulations
WO2010056909A1 (en) 2008-11-12 2010-05-20 Baxter International Inc. Purification of butyrylcholinesterase using membrane adsorption
US8546548B2 (en) 2009-05-27 2013-10-01 Baxter International Inc. Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
WO2011011753A1 (en) 2009-07-23 2011-01-27 Baxter International Inc. Manufacture of factor h (fh) and fh-derivatives from plasma
US8772462B2 (en) * 2010-05-26 2014-07-08 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
EA202090067A3 (ru) 2010-07-08 2020-07-31 Баксалта Инкорпорейтид Способ получения рекомбинантного adamts13 в культуре клеток
EP2596014B1 (en) * 2010-07-23 2018-11-28 Baxalta GmbH Manufacture of inter-alpha-inhibitor proteins (iaip) from plasma

Also Published As

Publication number Publication date
AU2011258111B2 (en) 2016-02-11
HRP20140944T1 (hr) 2014-12-05
JP6592120B2 (ja) 2019-10-16
EP2575762A2 (en) 2013-04-10
AU2010202125B1 (en) 2010-09-02
US20150133644A1 (en) 2015-05-14
CN109180776A (zh) 2019-01-11
MY173299A (en) 2020-01-14
KR20130080450A (ko) 2013-07-12
AU2021286395B2 (en) 2024-04-11
DK4039249T3 (da) 2026-03-16
MX2019004482A (es) 2019-08-30
TW201141879A (en) 2011-12-01
EA034530B1 (ru) 2020-02-18
JP6363676B2 (ja) 2018-07-25
US8940877B2 (en) 2015-01-27
AU2024204779A1 (en) 2024-08-01
DK2554160T3 (da) 2015-04-27
DK2575762T3 (da) 2014-10-13
MX2012013682A (es) 2013-01-28
MX364252B (es) 2019-04-17
CN102970975A (zh) 2013-03-13
HRP20141109T1 (hr) 2014-12-19
EP2575762B1 (en) 2014-07-09
CN104958761B (zh) 2021-01-01
PL2445482T3 (pl) 2015-01-30
EA201291355A1 (ru) 2013-04-30
EP2445482A1 (en) 2012-05-02
TWI531577B (zh) 2016-05-01
CN102970975B (zh) 2015-05-06
AR076800A1 (es) 2011-07-06
AU2018201371A1 (en) 2018-03-22
JP2016155798A (ja) 2016-09-01
MY161617A (en) 2017-04-28
AU2016202973A1 (en) 2016-05-26
EP2803349C0 (en) 2023-09-27
IL223149A0 (en) 2013-02-03
ES2525492T3 (es) 2014-12-23
EA201291367A1 (ru) 2013-09-30
EA023446B1 (ru) 2016-06-30
ES2536093T3 (es) 2015-05-20
CN104958761A (zh) 2015-10-07
JP2013527201A (ja) 2013-06-27
PL2803349T3 (pl) 2024-02-26
CL2014003430A1 (es) 2015-05-04
WO2011149472A1 (en) 2011-12-01
JP2017014297A (ja) 2017-01-19
TW201542584A (zh) 2015-11-16
HK1170168A1 (en) 2013-02-22
KR101593265B1 (ko) 2016-02-11
US8993734B2 (en) 2015-03-31
SG10201505161SA (en) 2015-08-28
JP5866345B2 (ja) 2016-02-17
JP2018080207A (ja) 2018-05-24
PT2575762E (pt) 2014-07-28
EA025826B1 (ru) 2017-02-28
MX349815B (es) 2017-08-09
CN103068365A (zh) 2013-04-24
EP2803349A1 (en) 2014-11-19
PT2554160E (pt) 2015-06-11
MX337028B (es) 2016-02-09
CL2012003290A1 (es) 2013-10-18
HRP20260340T1 (hr) 2026-04-24
HUE064400T2 (hu) 2024-03-28
HRP20150484T1 (hr) 2015-08-14
EP2554160B1 (en) 2015-02-25
US20240117009A1 (en) 2024-04-11
CN109180776B (zh) 2022-12-13
SG185724A1 (en) 2013-01-30
PL2575762T3 (pl) 2015-01-30
EA201691558A1 (ru) 2017-05-31
EP2445482B1 (en) 2014-08-27
US11136350B2 (en) 2021-10-05
AR082093A1 (es) 2012-11-14
CN104840946A (zh) 2015-08-19
AU2020200373B2 (en) 2022-01-13
AU2021286395A1 (en) 2022-01-20
US20110293638A1 (en) 2011-12-01
JP2013528183A (ja) 2013-07-08
CN103068365B (zh) 2015-07-08
AU2018201371B2 (en) 2019-10-31
AU2020200373A1 (en) 2020-02-13
ES2505465T3 (es) 2014-10-10
CO6660439A2 (es) 2013-04-30
US20180118782A1 (en) 2018-05-03
MX2012013689A (es) 2013-01-28
MY160551A (en) 2017-03-15
KR20160014119A (ko) 2016-02-05
TW201202263A (en) 2012-01-16
EP4039249A1 (en) 2022-08-10
IL223149A (en) 2017-02-28
PT2445482E (pt) 2014-11-03
HK1181682A1 (en) 2013-11-15
US12545703B2 (en) 2026-02-10
FI4039249T3 (fi) 2026-03-20
JP2016053016A (ja) 2016-04-14
IL223150A0 (en) 2013-02-03
EP4039249B1 (en) 2026-02-11
TWI543989B (zh) 2016-08-01
HK1183449A1 (en) 2013-12-27
AU2010224461B2 (en) 2011-08-04
KR101647617B1 (ko) 2016-08-10
BR112012029893A2 (pt) 2019-05-28
EA034602B1 (ru) 2020-02-25
CO6660438A2 (es) 2013-04-30
BR112012029893B1 (pt) 2022-09-06
EP2796128A1 (en) 2014-10-29
EA201500848A1 (ru) 2016-06-30
DK2445482T3 (da) 2014-09-22
BR112012029897A2 (pt) 2016-08-16
HK1213790A1 (zh) 2016-07-15
AU2011258111A1 (en) 2012-12-13
PT4039249T (pt) 2026-04-27
AR121861A2 (es) 2022-07-20
EP2554160A1 (en) 2013-02-06
US20130101579A1 (en) 2013-04-25
AR114228A2 (es) 2020-08-05
AU2010224461A1 (en) 2010-10-21
US20210403504A1 (en) 2021-12-30
AU2016202973B2 (en) 2017-12-07
HK1215931A1 (zh) 2016-09-30
EP2803349B1 (en) 2023-09-27
PL4039249T3 (pl) 2026-05-11
KR101716534B1 (ko) 2017-03-14
CA2800155A1 (en) 2011-12-01
PL2554160T3 (pl) 2015-07-31
TWI504607B (zh) 2015-10-21
HK1203838A1 (en) 2015-11-06
ES2959234T3 (es) 2024-02-22
KR20130109016A (ko) 2013-10-07
SG185725A1 (en) 2012-12-28
JP5876474B2 (ja) 2016-03-02
CA2800272A1 (en) 2011-12-01

Similar Documents

Publication Publication Date Title
BR112012029897A2 (pt) método para reduzir a quantidade de uma serina protease ou um zimogênio de serina protease em uma composição, método para preparar uma composição, composição de proteína derivada de plasma, e, método para tratamento de uma doença
CY2015014I1 (el) Μακροκυκλικοι αναστολεις της πρωτεασης σερινης της ηπατιτιδας c
IL207333A0 (en) Macrocyclic serine protease inhibitors
IL310186B2 (en) Plasma kallikrein binding proteins
ZA201307499B (en) Compositions and methods comprising serine protease variants
EP2576564A4 (en) MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS
EP2658859A4 (en) MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS
CL2014003055A1 (es) Procedimiento para preparar una composicion farmaceutica que comprende i) proporcionar una primera combinacion que comprende un compuesto inhibidor del proteasoma peptidico, una o mas ciclodextrinas y agua, y ii) poner en contacto la primera combinacion con un acido para formar una segunda combinacion; composicion farmaceutica.
BRPI0814056A2 (pt) Método para determinar a atividade do fator von willebrand na ausência de ristocetina e para determinar a adamts-13 protease
FI20095499A0 (fi) Sieniperäinen seriiniproteaasi ja sen käyttö
FI20106135A7 (fi) Sieniperäisen seriiniproteaasin variantteja
GB0809068D0 (en) The use of serine protease inhibitors
IT1395080B1 (it) Procedimento di lavorazione per la fabbricazione di una intersuola per calzature ed intersuola con esso ottenuta.
IL231892A0 (en) An improved process for the preparation of a 435tmc macrocyclic protease inhibitor intermediate
EP3054947A4 (en) Cathepsin cysteine protease inhibitors
EP2767547A4 (en) PROTEASE PROTEIN INHIBITOR, AND PROTEIN SOLUTION AND DETERGENT COMPOSITION CONTAINING THE SAME
IT1393050B1 (it) Procedimento di lavorazione per la fabbricazione di una calzatura e calzatura con esso ottenuta.
BRPI1015281A2 (pt) Polinucleitídeo isolado, cassete de expressão, planta, método para aumentar o nível de um polipeptídeo em um aplanta, método para aumentar a produtividade em uma planta e polipeptídeo isolado.
AU2011900234A0 (en) Serine protease inhibitors
AU2018208624A1 (en) Tripeptide epoxy ketone protease inhibitors
TH0901004135A (th) สารยับยั้งเซอรีนโปรตีเอสของตับอักเสบซีชนิดแมโครไซคลิก
HK1183873A (en) Macrocyclic hepatitis c serine protease inhibitors
HK1190146A (en) Macrocyclic hepatitis c serine protease inhibitors
HK1161235A (en) Cysteine protease inhibitors
GB201010084D0 (en) Cysteine protease inhibitors